Diabetes startup Omada Health finally went public after 14 years. Here's who made bank.

Omada Health, a chronic care company specializing in virtual care for conditions like prediabetes and weight management, went public at a $1.1 billion valuation, marking the second digital health IPO this year after Hinge Health. Omada's shares jumped nearly 50% above its initial pricing, opening at $23 after pricing at $19, driven by growth in areas like weight care related to GLP-1 drugs; major investors like Revelation Partners, US Venture Partners, and Andreessen Horowitz hold stakes worth $120M, $108.5M, and $106M respectively based on the opening price.

Analysis

Omada Health's successful IPO, the second in the digital health sector this year, signals a potential revival of investor interest following a multiyear downturn for such public market debuts. The company's shares demonstrated strong initial market traction, surging nearly 50% from an initial price of $19 to a high of $28.40 on the first day of trading, after opening at $23. This performance is underpinned by Omada Health's evolution from a prediabetes management focus to a broader chronic care provider, with significant recent growth in its weight care segment, driven by demand for companion services for patients using GLP-1 medications. The IPO valuation of $1.1 billion, largely consistent with its February 2022 Series E private valuation of over $1 billion, is a noteworthy achievement, especially when compared to other digital health companies like Hinge Health, which saw a considerable valuation decrease from its private rounds to its public offering. The fact that none of Omada's major investors, including Revelation Partners, US Venture Partners, and Andreessen Horowitz, sold shares in the IPO indicates continued confidence in the company's long-term prospects, aligning with the strategic view that effective chronic disease management will increasingly require integrated solutions combining pharmaceuticals with behavioral change support, a core tenet of Omada's model.

Key Decisions for Investors

• Investors should consider the positive momentum from Omada Health's strong IPO performance and its strategic alignment with the rapidly expanding GLP-1 companion care market, while remaining mindful of the typical volatility associated with newly public digital health entities.
• It is advisable to closely monitor Omada's execution on scaling its metabolic health programs and its success in securing and expanding contracts with employer and health plan clients, as these are critical drivers for future revenue growth and profitability.
• The decision of major institutional investors to retain their entire stakes through the IPO, coupled with a public valuation that largely held firm compared to its late-stage private funding, provides a degree of validation for the company's underlying fundamentals and growth strategy.